Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Ibrutinib

EU orphan designation number: EU/3/13/1203   
Active ingredient: Ibrutinib
Indication: Treatment of diffuse large B-cell lymphoma
Sponsor: Janssen-Cilag International NV
Turnhoutseweg 30, B-2340 Beerse, België

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/11/2013 Orphan designation EMA/OD/116/13 (2013)8050 of 13/11/2013